Redo Transcatheter Aortic Valve Replacement Safe, Effective
MONDAY, Sept. 11, 2023 (HealthDay News) -- Redo transcatheter aortic valve replacement (TAVR) procedures are as safe and effective as native TAVR in select patients, according to a study published online Aug. 31 in The Lancet.
Raj R. Makkar, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues assessed the safety and efficacy of redo TAVR in a national registry. The analysis included all consecutive patients in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (Nov. 9, 2011, to Dec. 30, 2022) who underwent TAVR with balloon-expandable valves in either failed transcatheter heart valves (redo TAVR; 1,320 patients) or native aortic valves (native TAVR; 349,271 patients).
The researchers found that the rates of procedural complications of redo TAVR were low (coronary compression or obstruction: 0.3 percent; intraprocedural death: 0.6 percent; conversion to open heart surgery: 0.5 percent) and overall similar to native TAVR. For death at 30 days (4.7 versus 4.0 percent) or one year (17.5 versus 19.0 percent) and stroke at 30 days (2.0 versus 1.9 percent) or one year (3.2 versus 3.5 percent), there were no significant differences between redo-TAVR and native-TAVR populations, respectively. At one year, redo TAVR reduced aortic valve gradients, although they were higher in the redo-TAVR group versus the native-TAVR group (15 versus 12 mm Hg). Rates of moderate or severe aortic regurgitation did not differ significantly between the redo-TAVR and native-TAVR groups at one year (1.8 versus 3.3 percent). Timing of redo TAVR (before or after one year of index TAVR) and index transcatheter valve type (balloon-expandable or non-balloon-expandable) did not significantly affect death or stroke after redo TAVR.
"Redo-TAVR with balloon-expandable valves might be a reasonable treatment for failed TAVR in selected patients," the authors write.
Edwards Lifesciences funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Related Posts
Pfizer to Seek FDA Approval of Boosters for Teens Ages 16-17
https://consumer.healthday.com/b-11-30-pfizer-to-s... Credit: HealthDay
Proportion of Mental Health Hospitalizations Increasing in Children
TUESDAY, March 28, 2023 (HealthDay News) -- The number and proportion of...
62 Symptoms Linked to SARS-CoV-2 Infection After 12 Weeks
THURSDAY, July 28, 2022 (HealthDay News) -- Severe acute respiratory syndrome...
Purrfect Pal: Robotic Cats May Help People With Dementia
MONDAY, Nov. 1, 2021 (HealthDay News) -- If you have a pet, you know that the...